Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 15/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.55 |
| ▸ | TNKS | O95271 | 2/20 | 0.54 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15205127 | 0.89 | TNKS (0.61) | CALCRLOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL12655389 | 0.86 | OPRM1 (0.55) | CALCRLOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL12402801 | 0.86 | CALCRL (0.55) | CALCRLOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL13351308 | 0.86 | OPRM1 (0.55) | CALCRLOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL14046378 | 0.86 | DRD2 (0.56) | CALCRLOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL12372810 | 0.86 | OPRM1 (0.52) | CALCRLOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL13380149 | 0.86 | CALCRL (0.56) | CALCRLOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL16456308 | 0.85 | TNKS (0.58) | CALCRLOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL12087688 | 0.85 | CALCRL (0.61) | CALCRLTNKS | |
| SCHEMBL13036892 | 0.85 | OPRM1 (0.65) | CALCRLOPRM1OPRD1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3628045-B1 | COMPOUNDS | UNIV SHEFFIELD (GB) | 2024-07-03 | — | — | EP | disclosed |
| US-20240208966-A1 | PROCESS FOR THE SYNTHESIS OF 1,3-DIHYDRO-IMIDAZO[4,5-B]PYRIDIN-2-ONE AND/OR DERIVATIVES THEREOF | SIEGFRIED AG (CH) | 2024-06-27 | — | — | US | disclosed |
| US-8952014-B2 | Pyrimidine derivatives which are CGRP—antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-10 | — | — | US | disclosed |
| US-8796260-B2 | Imidazobenzazepine CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20140128375-A1 | BENZAZEPINE COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2014-05-08 | — | — | US | disclosed |
| US-20120088755-A1 | Novel Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-12 | — | — | US | disclosed |
| WO-2010020628-A1 | NOVEL PRODUCTION METHOD FOR L-PIPERIDINE-4-YL-1,3-DIHYDRO-IMIDAZO [4,5-B] PYRIDINE-2-ONE AND MONO- AND DIHYDROCHLORIDES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088755-A1 | Novel Compounds | SLC26A4, F12, SLCO1B3 | CALCRL 501/4885OPRM1 151/4885OPRD1 456/4885 |
| US-20140128375-A1 | BENZAZEPINE COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS | BDKRB1, BDKRB2, CALCRL | CALCRL 3/4885OPRM1 88/4885OPRD1 109/4885 |
| US-20240208966-A1 | PROCESS FOR THE SYNTHESIS OF 1,3-DIHYDRO-IMIDAZO[4,5-B]PYRIDIN-2-ONE AND/OR DERIVATIVES THEREOF | PDXK, CYP1B1, CYP2F1 | CALCRL 2434/4885OPRM1 1412/4885OPRD1 1425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.